manganese superoxide dismutase plasmid liposome

Manganese superoxide dismutase plasmid liposome (MnSOD-PL) is a gene therapy drug consisting of a plasmid DNA encoding the human manganese superoxide dismutase (MnSOD) enzyme, encapsulated in a liposomal delivery system. The primary mechanism involves transfection of target cells with the human MnSOD gene, leading to increased expression of mitochondrial MnSOD protein. This enzyme acts as an antioxidant by catalyzing the conversion of superoxide radicals to hydrogen peroxide and oxygen, thereby protecting normal tissues from oxidative damage caused by ionizing radiation. Preclinical studies have demonstrated that administration of MnSOD-PL confers significant radioprotection in animal models, reducing tissue injury and improving survival after radiation exposure. Clinical trials have evaluated its safety and feasibility as an oral agent for chemoradiation-induced esophagitis in non-small-cell lung cancer patients[1][2][5]. The drug was initially developed at the University of Pittsburgh[2].

Other names

MnSOD-plasmid/liposomeMnSOD PLliposomal MnSOD-plasmid